Gastroenterology Highlights 2001-2002
Eamonn M. M. Quigley
Health Press, Jan 1, 2002 - Medical - 84 pages
The aim of this annual review is to identify, from the mass of publish=d work, those developments considered to be of greatest significance and to briefly summarize them in a digestible form. International authorities on gastroenterology, hepatology and endoscopy have contributed. Topics discussed include: oesophageal disorders; functional bowel disease; diseases of the liver; complications of liver disease; gastrointestinal endoscopy; diseases of the pancreas; disorders of the small bowel and malabsorption; inflammatory bowel disease; and gastrointestinal cancer diagnosis and management.
What people are saying - Write a review
We haven't found any reviews in the usual places.
achalasia acid acute adenocarcinoma alcoholic liver disease alfa-2b antibody Barrett's oesophagus biopsy bowel disease capsule cells chemoradiotherapy chemotherapy cholecystectomy chronic pancreatitis cirrhosis Clin clinical coeliac disease colon cancer colonoscopy colorectal cancer compared controlled Crohn's disease detection diagnosis disorders endoscopic ligation Engl enteroclysis examined faecal occult blood focal fundoplication gastric Gastroenterol Gastroenterology Gastrointest Endosc gastrointestinal genetic GORD Hepatology hiatus hernia high-grade dysplasia imaging improved increased risk inflammatory bowel infliximab interferon intestinal irritable bowel syndrome lesions lifestyle liver transplantation living donor long-term malabsorption malignant manometry markers mortality mucosal mutations neoplasia oesophageal adenocarcinoma oesophageal cancer overall survival pancreatic cancer pancreatic carcinoma patients undergoing patients with chronic pentoxifylline placebo pre-operative radiotherapy prevention radiotherapy randomized recent rectal cancer recurrence reflux disease resection ribavirin risk factor screening sensitivity significantly small bowel surgery surgical symptoms T-cells techniques therapeutic therapy treatment trial tumours versus visceral WHAT'S